✓ checked
trust me, bro:
here is the receipt.
the claim
Semaglutide reduces liver fat and inflammation in people with fatty liver disease.
the verdict
SUPPORTED
the evidence backs this
Recorded sources
9 sources for · 0 against
Is it true that Semaglutide reduces liver fat and inflammation in people with fatty liver disease?
Yes. Multiple systematic reviews and meta-analyses of randomized trials report that semaglutide reduces liver fat and lobular inflammation in people with NAFLD/NASH, and regulators have approved it for MASH; one review states GLP-1 receptor agonists reduce hepatic fat content and inflammation in biopsy-confirmed MASLD.
Verdict: SUPPORTED · 9 sources for, 0 against · Last checked
Evidence for · 9
Get citation
Semaglutide. (n.d.). en.wikipedia.org. https://en.wikipedia.org/wiki/Semaglutide
See more details
More for · 8
Get citation
Efficacy and safety of semaglutide in non-alcoholic fatty liver disease - PMC Lock. (n.d.). pmc.ncbi.nlm.nih.gov. https://doi.org/10.3748/wjg.v29.i37.5327
Get citation
Bandyopadhyay, S., Das, S., Samajdar, S. S., & Joshi, S. R. (2023). Role of semaglutide in the treatment of nonalcoholic fatty liver disease or non-alcoholic steatohepatitis: A systematic review and meta-analysis.. doi.org. https://doi.org/10.1016/j.dsx.2023.102849
Get citation
Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non‐alcoholic fatty liver disease assessed by magnetic resonance imaging. (n.d.). cir.nii.ac.jp. https://doi.org/10.1111/apt.16608
Get citation
Liao, C., Liang, X., Zhang, X., & Li, Y. (2023). The effects of GLP-1 receptor agonists on visceral fat and liver ectopic fat in an adult population with or without diabetes and nonalcoholic fatty liver disease: A systematic review and meta-analysis. doi.org. https://doi.org/10.1371/journal.pone.0289616
Get citation
Mantovani, A., Byrne, C. D., & Targher, G. (2022). Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review.. doi.org. https://doi.org/10.1016/S2468-1253(21)00261-2
Get citation
FDA Approves Treatment for Serious Liver Disease Known as ‘MASH’ | FDA. (n.d.). fda.gov. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-serious-liver-disease-known-mash
Get citation
106-OR: Semaglutide Reduces Tumor Burden in the GAN Diet-Induced Obese and Biopsy-Confirmed Mouse Model of MASH with Advanced Fibrosis and HCC. (2024). doi.org. https://doi.org/10.2337/db24-106-or
Get citation
Giannakogeorgou, A. & Roden, M. (2024). Role of lifestyle and glucagon-like peptide-1 receptor agonists for weight loss in obesity, type 2 diabetes and steatotic liver diseases.. doi.org. https://doi.org/10.1111/apt.17848
Receipt History
Anyone with this link can read the claim and its public receipt, including any
personal information in that text. Open permanent receipt.
Check your own claim
Challenge the receipt
Requests are recorded for review. This does not start an automatic check
or guarantee a response time.
Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.
This receipt is an automated verdict against our published method · not an opinion about any author or publication.
Terms · Privacy · How verdicts work
Terms · Privacy · How verdicts work